Analysed TRINITY BIOTECH PLC-SPON ADR (TRIB:NASDAQ) News Sources
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
10-04-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
09-04-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Track Lower in Tuesday Trading
07-04-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading
25-03-2026
yahoo.com
Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test
23-03-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading
19-03-2026
yahoo.com
Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren’s Syndrome
18-03-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Higher Tuesday
17-03-2026
yahoo.com
What is the current price of TRINITY BIOTECH PLC-SPON ADR (TRIB:NASDAQ)?
The current price of TRINITY BIOTECH PLC-SPON ADR (TRIB:NASDAQ) is $0.7143.
TRINITY BIOTECH PLC-SPON ADR (TRIB:NASDAQ) absolute price change since previous trading day?
The absolute price change of TRINITY BIOTECH PLC-SPON ADR (TRIB:NASDAQ) since the previous trading day is $0.0167.
TRINITY BIOTECH PLC-SPON ADR (TRIB:NASDAQ) percentage price change since previous trading day?
The percentage price change of TRINITY BIOTECH PLC-SPON ADR (TRIB:NASDAQ) since the previous trading day is 2.3939%.
What is the most recent average sentiment score for TRINITY BIOTECH PLC-SPON ADR (TRIB:NASDAQ)?
The most recent average sentiment score for TRINITY BIOTECH PLC-SPON ADR (TRIB:NASDAQ) is 62 out of 100.
What is the most recent average sentiment for TRINITY BIOTECH PLC-SPON ADR (TRIB:NASDAQ)?
The most recent sentiment for TRINITY BIOTECH PLC-SPON ADR (TRIB:NASDAQ) is .
SEC-8K** Filing Available For TRINITY BIOTECH PLC-SPON ADR (TRIB:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.